Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies-Reference-Cited by-同舟云学术

Efficacy and safety of CAR19/22 T-cell cocktail therapy in patients with refractory/relapsed B-cell malignancies

Published:2020-01-02 Issue:1 Volume:135 Page:17-27
ISSN:0006-4971
Container-title:Blood
language:en
Short-container-title:

Author:

Wang Na¹²,Hu Xuelian¹²,Cao Wenyue¹²,Li Chunrui¹²,Xiao Yi¹²,Cao Yang¹²,Gu Chaojiang³⁴,Zhang Shangkun⁴,Chen Liting¹²^ORCID,Cheng Jiali¹²,Wang Gaoxiang¹²,Zhou Xiaoxi¹²,Zheng Miao¹²,Mao Xia¹²,Jiang Lijun¹²,Wang Di¹²,Wang Qiuxiang¹²,Lou Yaoyao¹²,Cai Haodong¹²,Yan Dandan⁵,Zhang Yicheng¹²,Zhang Tongcun³⁴,Zhou Jianfeng¹²,Huang Liang¹²^ORCID

Affiliation:

1. Department of Hematology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China;

2. Immunotherapy Research Center for Hematologic Diseases of Hubei Province, Wuhan, China;

3. College of Life Science and Health, Wuhan University of Science and Technology, Wuhan, China;

4. Wuhan Bio-Raid Biotechnology Co., Ltd., Wuhan, China; and

5. Department of Health Toxicology, Ministry of Education (MOE) Key Laboratory of Environment and Health, School of Public Health, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Abstract

Relapse following chemeric antigen receptor (CAR) T-cell therapy can arise from progressive loss of the CAR T cells or from loss of the target antigen by tumor cells. Wang et al report that using a mix of CAR T cells targeting CD19 and CD22 reduces relapse with antigen-negative tumor cells. However, a lack of CAR T-cell persistence leads to increased relapse with antigen-positive cells.

Publisher

American Society of Hematology

Subject

Cell Biology,Hematology,Immunology,Biochemistry

Link

http://ashpublications.org/blood/article-pdf/135/1/17/1550410/bloodbld2019000017.pdf

Reference43 articles.

1. The Principles of Engineering Immune Cells to Treat Cancer;Lim;Cell,2017

2. Immune targets and neoantigens for cancer immunotherapy and precision medicine;Wang;Cell Res,2017

3. Chimeric Antigen Receptor Therapy;June;N Engl J Med,2018

4. Therapeutic T cell engineering;Sadelain;Nature,2017

5. CAR T cell immunotherapy for human cancer;June;Science,2018

Cited by 200 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. How can we improve the successful identification of patients suitable for CAR-T cell therapy?;Expert Review of Molecular Diagnostics;2024-09-11

2. Antigen escape in CAR-T cell therapy: Mechanisms and overcoming strategies;Biomedicine & Pharmacotherapy;2024-09

3. 3D live imaging and phenotyping of CAR-T cell mediated-cytotoxicity using high-throughput Bessel oblique plane microscopy;Nature Communications;2024-08-06

4. A bibliometric and knowledge-map study on the treatment of hematological malignancies with CAR-T cells from 2012 to 2023;Human Vaccines & Immunotherapeutics;2024-07-03

5. Advances in the treatment of Philadelphia chromosome negative acute lymphoblastic leukemia;Blood Reviews;2024-07